Advisor Group Holdings, Inc. Bio Line Rx Ltd. Transaction History

Advisor Group Holdings, Inc.

$44.4 Billion
Q2 2025

A detailed history of Advisor Group Holdings, Inc. transactions in Bio Line Rx Ltd. stock. As of the latest transaction made, Advisor Group Holdings, Inc. holds 6 shares of BLRX stock, worth $22. This represents 0.0% of its overall portfolio holdings.

Number of Shares

Holding current value

$22

% of portfolio

0.0%

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 13, 2025	BUY	$2.43 - $5.93 $14 - $35	6 New	6 $0
Q4 2024 Jun 06, 2025	BUY	$0.2 - $0.6 $241 - $723	1,206 New	1,206 $0
Q3 2024 Nov 13, 2024	SELL	$0.53 - $0.87 $106 - $174	-200 Reduced 14.22%	1,206 $0
Q2 2024 Aug 13, 2024	BUY	$0.56 - $0.86 $112 - $172	200 Added 16.58%	1,406 $0
Q1 2024 May 10, 2024	SELL	$1.03 - $1.56 $13,512 - $20,465	-13,119 Reduced 91.58%	1,206 $1,000
Q4 2023 Feb 12, 2024	SELL	$1.31 - $1.86 $12,929 - $18,358	-9,870 Reduced 40.79%	14,325 $22,000
Q3 2023 Nov 13, 2023	BUY	$1.23 - $2.45 $5,281 - $10,520	4,294 Added 21.58%	24,195 $44,000
Q2 2023 Aug 10, 2023	SELL	$0.96 - $1.78 $10,609 - $19,672	-11,052 Reduced 35.71%	19,901 $31,000
Q1 2023 May 12, 2023	BUY	$0.56 - $0.89 $16,658 - $26,474	29,747 Added 2466.58%	30,953 $27,000
Q4 2022 Feb 10, 2023	SELL	$0.57 - $0.95 $5,387 - $8,978	-9,451 Reduced 88.68%	1,206 $0
Q3 2022 Nov 14, 2022	SELL	$0.88 - $1.91 $2,455 - $5,328	-2,790 Reduced 20.75%	10,657 $10,000
Q2 2022 Aug 10, 2022	SELL	$1.06 - $1.82 $5,427 - $9,318	-5,120 Reduced 27.58%	13,447 $17,000
Q1 2022 May 04, 2022	BUY	$1.46 - $2.18 $16,290 - $24,324	11,158 Added 150.6%	18,567 $31,000
Q3 2021 Nov 05, 2021	BUY	$2.65 - $3.35 $17,278 - $21,842	6,520 Added 733.41%	7,409 $20,000
Q1 2021 May 13, 2021	BUY	$2.38 - $4.0 $1,785 - $3,000	750 Added 539.57%	889 $2,000
Q1 2020 May 18, 2020	BUY	$1.11 - $2.6 $154 - $361	139 New	139 $0

Others Institutions Holding BLRX

# of Institutions

Shares Held

852K

Call Options Held

Put Options Held

View Full List

About BioLineRx Ltd.

Ticker BLRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,524,500
Market Cap $231M
Description
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials ...

More about BLRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisor Group Holdings, Inc. with notifications on news.

Account